viewWest Wits Mining Limited

West Wits Mining secures funds as trading to recommence today

The company is focused on conglomerate gold in South Africa’s Witwatersrand basin and WA’s Pilbara region.

West Wits Mining Ltd - West Wits Mining to return to boarse today
The ASX has returned West Wits securities to its list

West Wits Mining Ltd (ASX:WWI) shares will recommence trading today on the ASX after the company completed a capital raising from sophisticated investors yesterday.

The Victorian company raised a final $735,000 sum yesterday from high-quality investors, allowing its expected return to trading this morning.

Explorer West Wits launched the capital raising last week, receiving commitments for 122.5 million ordinary shares at a 0.6 cent issue price.

Conglomerate gold-focused West Wits expects the cap raise will allow it to focus on its planned activities as it expects a mining right grant for its Witwatersrand Gold Project in South Africa, perhaps by September 2019.

The company also has assets in the Paterson province of WA’s prospective Pilbara region and hopes to unlock value in Indonesia at another gold project, Derewo River.

West Wits’ projects in the Pilbara includes the Mt Cecelia Gold Project, which is 70 kilometres west of Rio Tinto's (ASX:RIO) Winu copper-gold discovery and near Rumble Resources Ltds (ASX:RTE) Braeside project.

Quick facts: West Wits Mining Limited

Price: 0.038 AUD

Market: ASX
Market Cap: $45.03 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of West Wits Mining Limited named herein, including the promotion by the Company of West Wits Mining Limited in any Content on the Site, the...


Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

5 hours, 54 minutes ago

2 min read